CONTEXT
Institutional academic-industry relationships have the potential of creating institutional conflicts of interest. To date there are no empirical data to support the establishment and evaluation of institutional policies and practices related to managing these relationships.
OBJECTIVE
To conduct a national survey of department chairs about the nature, extent, and consequences of institutional-academic industry relationships for medical schools and teaching hospitals.
DESIGN, SETTING, AND PARTICIPANTS
National survey of department chairs in the 125 accredited allopathic medical schools and the 15 largest independent teaching hospitals in the United States, administered between February 2006 and October 2006.
MAIN OUTCOME MEASURE
Types of relationships with industry.
RESULTS
A total of 459 of 688 eligible department chairs completed the survey, yielding an overall response rate of 67%. Almost two-thirds (60%) of department chairs had some form of personal relationship with industry, including serving as a consultant (27%), a member of a scientific advisory board (27%), a paid speaker (14%), an officer (7%), a founder (9%), or a member of the board of directors (11%). Two-thirds (67%) of departments as administrative units had relationships with industry. Clinical departments were more likely than nonclinical departments to receive research equipment (17% vs 10%, P = .04), unrestricted funds (19% vs 3%, P < .001), residency or fellowship training support (37% vs 2%, P < .001), and continuing medial education support (65% vs 3%, P < .001). However, nonclinical departments were more likely to receive funding from intellectual property licensing (27% vs 16%, P = .01). More than two-thirds of chairs perceived that having a relationship with industry had no effect on their professional activities, 72% viewed a chair's engaging in more than 1 industry-related activity (substantial role in a start-up company, consulting, or serving on a company's board) as having a negative impact on a department's ability to conduct independent unbiased research.
CONCLUSION
Overall, institutional academic-industry relationships are highly prevalent and underscore the need for their active disclosure and management.
[1]
Jordan J. Cohen,et al.
Health industry practices that create conflicts of interest: a policy proposal for academic medical centers.
,
2006,
JAMA.
[2]
T. Brennan,et al.
Financial conflicts of interest in physicians' relationships with the pharmaceutical industry--self-regulation in the shadow of federal prosecution.
,
2005,
The New England journal of medicine.
[3]
D. Blumenthal.
Doctors and drug companies.
,
2004,
The New England journal of medicine.
[4]
V. Rolla,et al.
On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health
,
2004
.
[5]
E. Campbell,et al.
Institutional Academic Industry Relationship: Results of Interviews with University Leaders
,
2004,
Accountability in research.
[6]
Robert C Barrier,et al.
A population-based study of the prevalence and influence of gifts to radiation oncologists from pharmaceutical companies and medical equipment manufacturers.
,
2003,
International journal of radiation oncology, biology, physics.
[7]
G. Masiero,et al.
Universities in the marketplace: the commercialization of higher education
,
2003
.
[8]
G. Loewenstein,et al.
A social science perspective on gifts to physicians from industry.
,
2003,
JAMA.
[9]
C. Gross,et al.
Scope and impact of financial conflicts of interest in biomedical research: a systematic review.
,
2003,
JAMA.
[10]
T. Bodenheimer,et al.
Uneasy alliance--clinical investigators and the pharmaceutical industry.
,
2000,
The New England journal of medicine.
[11]
D. Rothman,et al.
Medical professionalism--focusing on the real issues.
,
2000,
The New England journal of medicine.
[12]
Floyd J. Fowler,et al.
Improving Survey Questions: Design and Evaluation
,
1995
.
[13]
S. Krimsky,et al.
Science in the private interest: has the lure of profits corrupted biomedical research?
,
2006,
IEEE Technology and Society Magazine.
[14]
A. Andreasen.
On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health
,
2005
.
[15]
Jerry Avorn,et al.
Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs
,
2004
.